Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.39 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.39 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 6/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | G6PD | P11413 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29532347 | 1.00 | ALDH1A1 (0.39) | ALDH1A1ALOX15TSHRTDP1CYP3A4 | |
| SCHEMBL28415561 | 0.85 | ALDH1A1 (0.40) | ALDH1A1ALOX15TSHRTDP1CYP3A4 | |
| SCHEMBL24251659 | 0.80 | ALDH1A1 (0.44) | ALDH1A1TDP1MAPTKDM4EMEN1 | |
| SCHEMBL28973011 | 0.78 | CYP1A2 (0.44) | ALDH1A1CYP3A4MAPTMEN1THRB | |
| SCHEMBL28347645 | 0.77 | AR (0.35) | — | |
| SCHEMBL17490379 | 0.77 | NPSR1 (0.46) | ALDH1A1HPGDMAPTMEN1HSP90AA1 | |
| SCHEMBL31289142 | 0.77 | MERTK (0.41) | ALDH1A1TSHRTDP1CYP3A4MAPT | |
| SCHEMBL17490467 | 0.76 | HCRTR1 (0.35) | ALDH1A1ALOX15TSHRTDP1CYP3A4 | |
| SCHEMBL29532057 | 0.76 | HCRTR1 (0.35) | ALDH1A1ALOX15TSHRTDP1CYP3A4 | |
| SCHEMBL28500092 | 0.74 | ALDH1A1 (0.35) | ALDH1A1ALOX15TSHRTDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3998268-B1 | COMPOUND FOR INHIBITING EGFR KINASE AND PREPARATION METHOD AND USE THEREOF | WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) | 2024-12-18 | — | — | EP | disclosed |
| US-11993598-B2 | Compounds for inhibiting EGFR kinase, preparation methods and uses thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2024-05-28 | — | — | US | disclosed |
| CN-112638897-B | EGFR kinase inhibitor and preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-114026090-B | Compound for inhibiting EGFR kinase and preparation method and application thereof | 微境生物医药科技(上海)有限公司 | 2023-01-06 | — | — | CN | disclosed |
| EP-3998268-A1 | COMPOUND FOR INHIBITING EGFR KINASE AND PREPARATION METHOD AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
| EP-3998268-A1 | COMPOUND FOR INHIBITING EGFR KINASE AND PREPARATION METHOD AND USE THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
| CN-114026090-A | Compound for inhibiting EGFR kinase and preparation method and application thereof | 微境生物医药科技(上海)有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-20210230161-A1 | COMPOUNDS FOR INHIBITING EGFR KINASE, PREPARATION METHODS AND USES THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2021-07-29 | — | — | US | disclosed |
| US-20210230161-A1 | COMPOUNDS FOR INHIBITING EGFR KINASE, PREPARATION METHODS AND USES THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2021-07-29 | — | — | US | disclosed |
| WO-2021000912-A1 | COMPOUND FOR INHIBITING EGFR KINASE AND PREPARATION METHOD AND USE THEREOF | 微境生物医药科技(上海)有限公司 | 2021-01-07 | — | — | WO | disclosed |
| CN-112174961-A | Compound for inhibiting EGFR kinase and preparation method and application thereof | 微境生物医药科技(上海)有限公司 | 2021-01-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230161-A1 | COMPOUNDS FOR INHIBITING EGFR KINASE, PREPARATION METHODS AND USES THEREOF | EGFR, ERBB2, ERBB4 | ALDH1A1 3389/4885ALOX15 4165/4885TSHR 1698/4885 |
| US-11993598-B2 | Compounds for inhibiting EGFR kinase, preparation methods and uses thereof | EGFR, ERBB2, ERBB4 | ALDH1A1 3389/4885ALOX15 4165/4885TSHR 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.